tbuckley/cabot-search huggingface dataset:
Inhaled tranexamic acid improved recovery from hemoptysis compared with placebo
Authors: Andrew S. Dunn
Journal: Annals of Internal Medicine (2019)

ACP Journal Club16 April 2019Inhaled tranexamic acid improved recovery from hemoptysis compared with placeboAndrew S. Dunn, MD, MPHAndrew S. Dunn, MD, MPHMount Sinai Health System, New York, New York, USA (A.S.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ201904160-045 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationWand O, Guber E, Guber A, et al. Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial. Chest. 2018;154:1379-84. https://pubmed.ncbi.nlm.nih.gov/30321510Clinical Impact RatingsHospitalists: Pulmonology: References1 Wang JW, Chen B, Lin PC, et al. The efficacy of combined use of rivaroxaban and tranexamic acid on blood conservation in minimally invasive total knee arthroplasty a double-blind randomized, controlled trial. J Arthroplasty. 2017;32:801-06. [PMID: 27663190] Google Scholar2 Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev. 2016;11:CD008711. [PMID: 27806184] Google Scholar3 Bellam BL, Dhibar DP, Suri V, et al. Efficacy of tranexamic acid in haemoptysis: A randomized, controlled pilot study. Pulm Pharmacol Ther. 2016;40:80-3. [PMID: 27470681] Google Scholar Author, Article, and Disclosure InformationAffiliations: Mount Sinai Health System, New York, New York, USA (A.S.D.)This article was published at Annals.org on 2 April 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 April 2019Volume 170, Issue 8Page: JC45KeywordsBlood volumeHemorrhageLength of stayLung and intrathoracic tumorsPulmonary diseasesPulmonary medicineRenal failureSaline solutionsThorax ePublished: 16 April 2019 Issue Published: 16 April 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
FRI-440-Management of acute hepatic porphyria attacks in europe and united states: EXPLORE international, prospective, natural history study
Authors: Eliane Sardh, Manisha Balwani, Laurent Gouya, D Montgomery Bissell, David Rees, Ulrich Stölzel, John Phillips, Raili Kauppinen, Janneke Langendonk, Robert Desnick, Jean Charles Deybach, Herbert Bonkovsky, Charles Parker, Hetanshi Naik, Mike Badminton, Penelope Stein, Elisabeth Minder, Jerzy Windyga, Pavel Martasek, Maria Domenica Cappellini, Paolo Ventura, Pauline Harper, Sverre Sandberg, Aasne Aarsand, Felix Alegre, Aneta Ivanova, Neila Talbi, John Ko, Dalia Cahana-Amitay, Amy Chan, Quinn Dinh, Craig Penz, Amy Simon, Tim Lin, Karl Anderson
Journal: Journal of Hepatology (2019)
Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer
Authors: I. Kotsantis, P. Economopoulou, A. Psyrri, E. Maratou, D. Pectasides, H. Gogas, N. Kentepozidis, G. Mountzios, G. Dimitriadis, S. Giannouli
Journal: Annals of Oncology (2019)

Background: Insulin-like growth factor 1(IGF-1) signaling pathway has been suggested as an important oncogenic mediator in various malignancies, including lung cancer. In this study, we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-Binding Protein 3 (IGF-BP3) before and after chemotherapy or chemoradiotherapy treatment in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) and their potential correlation with response to therapy and patient survival. Methods: Seventy-three patients with stage III/IV NSCLC were included in the study. Expression of IGF1, IGF2, and IGFBP3 was evaluated in peripheral blood samples in two separate time points, at baseline and 3 months post treatment. Analysis and quantification of circulating levels of IGF-1, IGF-2, IGF-BP3 were performed by total ELISA technique. IGF-1/IGF-BP3 ratio is considered an indicator of IGF-1 bioavailability. Results: In univariate analysis, the median value of IGF-1 after treatment (130.80 vs 98.00 ng/ml, p = 0.087), and the median ratio of IGF-1/IGF-BP3 (0.01044 vs 0.00678, p = 0.056) were higher in responders. Further analysis of the variation of each biomarker before and after treatment showed that the median value of IGF-1 was decreased after treatment in the total population (125.82 from 133.4 ng/ml, p = 0.087), albeit no difference was found between subgroups. In addition, the median value of IGF-1/IGF-BP3 ratio was found to be lower after treatment in the total population (0.01006 from 0.01252, p = 0.011). Importantly, the post-treatment value of the ratio was significantly reduced in responders (0.01044 from 0.01255, p = 0.02). No correlation was found between variation in biomarker values, patient OS and PFS. Conclusions: In a cohort of patients with stage III/IV NSCLC treated with chemotherapy or chemoradiotherapy, reduction of IGF-1/IGF-BP3 ratio, which is an indicator of IGF-1 bioavailability, was statistically significant in patients that responded to treatment. If validated in larger cohorts, our results support the use of IGF-1/IGFBP3 as a predictive tool for response to chemotherapy in NSCLC. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice
Authors: M. Faehling, B. Schwenk, M. Kopp, S. Fallscheer, S. Kramberg, R. Eckert
Journal: Annals of Oncology (2019)

Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1-antibodies have been introduced in the treatment of advanced NSCLC since 2015 based on randomized trials showing unprecedented advantages in OS with hazard ratios (HR) often between 0.5 and 0.6. The impact of these treatments on survival in routine clinical practice and the role of tumor load have not been studied. Methods: 1334 patients diagnosed with NSCLC in our certified lung-cancer center from 2006 – September 2018 were studied. OS of immuno-oncologically treated patients ("IO-patients") who received treatment with a PD-1 antibody (nivolumab [n = 76] or pembrolizumab [n = 51]) or a PD-L1-antibody (atezolizumab [n = 4] or durvalumab [n = 12]) was compared to historic controls treated in our center before availability of IO-treatment using case-control analysis. IO-patients and historic controls were individually matched for stage, performance state, histology, smoking history, gender, age, and initial treatment mode (palliative vs. curative). Matching was performed blinded to patient number, treatment, and survival. The study was approved by the local ethics committee (Landesärztekammer Baden-Württemberg F-2017-004). Results: IO-patients had significantly longer OS than historic controls (21.8 vs. 10.7 months, HR 0,55, CI 0.40 - 0.75, p = 0.0002). The benefit was more pronounced in patients with lower tumor stage (HR 0.364 [stage III], 0.407 [IVA], 0.605 [IVB]) or smaller tumor size (HR 0.32 [RECIST < 65], 0.38 [RECIST 65-100], 0.56 [RECIST 101-145], 0.86 [RECIST > 145]). Conclusions: IO-patients in routine clinical practice showed significant benefit in OS with hazard ratios comparable to that reported in phase III trials. The benefit was greater in patients with lower tumor load. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: M. Faehling: Advisory boards: AstraZenenca, BMS, MSD, Roche. All other authors have declared no conflicts of interest.
Clock Gene Disruption Is an Initial Manifestation of Inflammatory Bowel Diseases
Authors: Yael Weintraub, Shlomi Cohen, Nava Chapnik, Amir Ben-Tov, Anat Yerushalmy-Feler, Iris Dotan, Riva Tauman, Oren Froy
Journal: Clinical Gastroenterology and Hepatology (2019)
SAT-334-Liver steatosis in HIV-positive patients with and without HBV coinfection accessing care in a programmatic setting in Africa
Authors: Giovanni Villa, Richard Phillips, Colette Smith, Dorcas Owusu, Adam Abdullahi, Harrison Austin, Laila Sayeed, David Chadwick, Sanjay Bhagani, Anna Maria Geretti
Journal: Journal of Hepatology (2019)
SAT-174-Formation of the occult chronic hepatitis B during antiviral therapy in patients with HIV + HBV + HDV + HCV infection: Clinical cases
Authors: Konstantin Zhdanov, Ilnur Gabdrakhmanov, Yulia Ostankova, Konstantin Kozlov, Vitalii Sukachev, Denis Gusev, Aleksandr Semenov, Svetlana Romanova, Svetlana Kizhlo, Sergey Ignat’ev, Dmitrii Schakhmanov
Journal: Journal of Hepatology (2019)
Abstract 1504: Scn4b Is A Genetic Modifier Of Cardiac Conduction Disease In Mice
Authors: Brendon P Scicluna, Carol A Remme, Arie O Verkerk, Ahmad S Amin, Michael W Tanck, Leander Beekman, Vera H Deneer, Catherine Chevalier, Fumitaka Oyama, Haruko Miyazaki, Nobuyuki Nukina, Denis Escande, Remi Houlgatte, Jacques M de Bakker, Marieke Veldkamp, Hanno L Tan, Arthur A Wilde, Connie R Bezzina
Journal: Circulation (2008)

Background: Conduction slowing of the cardiac electrical impulse may evoke cardiac arrhythmias that result in sudden cardiac death. We have previously generated a mouse model of cardiac Na+ channel...
Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials—Reply
Authors: Jonathan Kimmelman, Marcin Waligora, Holly Fernandez Lynch
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Epigenome-wide association study of lung function level and its change
Authors: Medea Imboden, Matthias Wielscher, Faisal I. Rezwan, André F.S. Amaral, Emmanuel Schaffner, Ayoung Jeong, Anna Beckmeyer-Borowko, Sarah E. Harris, John M. Starr, Ian J. Deary, Claudia Flexeder, Melanie Waldenberger, Annette Peters, Holger Schulz, Su Chen, Shadia Khan Sunny, Wilfried J.J. Karmaus, Yu Jiang, Gertraud Erhart, Florian Kronenberg, Ryan Arathimos, Gemma C. Sharp, Alexander John Henderson, Yu Fu, Päivi Piirilä, Kirsi H. Pietiläinen, Miina Ollikainen, Asa Johansson, Ulf Gyllensten, Maaike de Vries, Diana A. van der Plaat, Kim de Jong, H. Marike Boezen, Ian P. Hall, Martin D. Tobin, Marjo-Riitta Jarvelin, John W. Holloway, Deborah Jarvis, Nicole M. Probst-Hensch
Journal: European Respiratory Journal (2019)

Previous reports link differential DNA methylation (DNAme) to environmental exposures that are associated with lung function. Direct evidence on lung function DNAme is, however, limited. We undertook an agnostic epigenome-wide association study (EWAS) on pre-bronchodilation lung function and its change in adults. In a discovery–replication EWAS design, DNAme in blood and spirometry were measured twice, 6–15 years apart, in the same participants of three adult population-based discovery cohorts (n=2043). Associated DNAme markers (p&lt;5×10 −7 ) were tested in seven replication cohorts (adult: n=3327; childhood: n=420). Technical bias-adjusted residuals of a regression of the normalised absolute β-values on control probe-derived principle components were regressed on level and change of forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC) and their ratio (FEV 1 /FVC) in the covariate-adjusted discovery EWAS. Inverse-variance-weighted meta-analyses were performed on results from discovery and replication samples in all participants and never-smokers. EWAS signals were enriched for smoking-related DNAme. We replicated 57 lung function DNAme markers in adult, but not childhood samples, all previously associated with smoking. Markers not previously associated with smoking failed replication. cg05575921 ( AHRR (aryl hydrocarbon receptor repressor)) showed the statistically most significant association with cross-sectional lung function (FEV 1 /FVC: p discovery =3.96×10 −21 and p combined =7.22×10 −50 ). A score combining 10 DNAme markers previously reported to mediate the effect of smoking on lung function was associated with lung function (FEV 1 /FVC: p=2.65×10 −20 ). Our results reveal that lung function-associated methylation signals in adults are predominantly smoking related, and possibly of clinical utility in identifying poor lung function and accelerated decline. Larger studies with more repeat time-points are needed to identify lung function DNAme in never-smokers and in children.
GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial
Authors: George Dalekos, Pietro Invernizzi, Frederik Nevens, Van Vlierberghe Hans, Ehud Zigmond, Raul J. Andrade, Ziv Ben Ari, Michael Heneghan, Jonathan Huang, Stephen Harrison, Gerald Minuk, Schattenberg JörnPD Dr., Christophe Moreno, John Vierling, Catherine Vincent, Christopher Bowlus, Yoav Lurie, Luigi Muratori, Grazia Niro, Gideon Hirschfield, Anthony Post, Stefan Zeuzem, Tania Welzel, Chin Lye Ch’ng, Cynthia Levy, Michael Miller, Agustin Albillos, Jane D. Collier, Lynsey Corless, Douglas Dieterich, Andreas E Kremer, George Papatheodoridis, David Romeo, Marina Silveira, David Bernstein, Michal Cohen-Naftaly, Annarosa Floreani, Brian Borg, Elizabeth Carey, Coral Hollywood, Benedict Maliakkal, Marco Marzioni, Mordechai Rabinovitz, Christian Rupp, David Sheridan, Carmen Stanca, Mark G Swain, Ella Veitsman, P Spyridon Dourakis, Philippe Wiese
Journal: Journal of Hepatology (2019)
PS-111-Six month interim results of MSDC-0602 K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)
Authors: Stephen Harrison, Guy Neff, Julie Iwashita, Jules Lee, Don Lazas, Kenneth Cusi, Arun Sanyal, Rohit Loomba, Naim Alkhouri, Juan Frias, Sam Moussa, Howard Dittrich
Journal: Journal of Hepatology (2019)
THU-040-AARC score: A dynamic model to predict outcome in acute on chronic liver failure patients
Authors: karan kumar, Ashok Kumar Choudhury, Mamun Al Mahtab, Salimur Rahman, Mohd. Shahinul Alam, Harshad Devarbhavi, yk Chawla, rk Dhiman, Ajay Duseja, Sunil Taneja, Shiv K Sarin, Irene Paulson, Priyanka Jain, Guresh Kumar, Ashish Goel, ce Eapen, Ajit Sood, Vandana Midha, Omesh Goyal, Akash Shukla, Samir Shah, Chetan Kalal
Journal: Journal of Hepatology (2019)
THU-380-DLL4 restores damaged liver by protecting hepatocytes and enhancing cholangiocyte differentiation
Authors: Jun Li, Suwan Sun, Dongyan Shi, Jiaojiao Xin, Jing Jiang, Qian Zhou, Jiang Li, Li Shao, Lingling Yang, Hozeifa Mohamed Hassan, Yinyun Lu, Beibei Guo, Xingping Zhou
Journal: Journal of Hepatology (2019)
Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract
Authors: Rayane S.C.M.Q. Antonino, Thais L. Nascimento, Edilson R. de Oliveira Junior, Leonardo G. Souza, Aline C. Batista, Eliana M. Lima
Journal: Journal of Controlled Release (2019)
PS-194-Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: Phase 2 study results
Authors: Ulrich Baumann, Ekkehard Sturm, Florence Lacaille, Emmanuel Gonzales, Henrik Arnell, Björn Fischler, Marianne Hørbyjørgensen, Richard Thompson, Jan Mattsson, Per-Goran Gillberg, Kristina Torfgard
Journal: Journal of Hepatology (2019)
Abstract 19671: Therapeutic Angiogenesis of Human iPS Cell-Derived Endothelial and Mural Cells Incorporated With Gelatin Sponge Scaffold in a Murine Hindlimb Ischemia Model
Authors: Shinichi Tsumaru, Hidetoshi Masumoto, Miki Yoshioka, Keiko Yoshizawa, Masahide Kawatou, Takeshi Ikuno, Tadashi Ikeda, Yasuhiko Tabata, Jun K Yamashita, Kenji Minatoya
Journal: Circulation (2017)

Background: To standardize stem cell-based therapeutic angiogenesis for peripheral artery disease, a transplantation strategy to achieve efficient and sustainable therapeutic effect is required. In this study, we have investigated therapeutic effects of human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) and vascular mural cells (MCs) incorporated with gelatin sponge (GS) scaffold in a murine hindlimb ischemia model. Methods: A hindlimb ischemia model was established in male 8-week-old NOD/SCID mice. We induced ECs and MCs from hiPSCs using a 2-dimensional high-density culture, respectively. We prepared GS by the homogenization of the aqueous solution of gelatin. We prepared a mixture of induced ECs and MCs (1.0 x106 ECs+1.0 x106 MCs / mouse) with or without GS. We injected them into the ischemic thigh muscles just after induction of ischemia. We compared control group (medium), vehicle group (GS + medium) and treatment group (hiPSC-derived ECs and MCs) with or without GS. Measurem...
The incidence of hepatitis B virus (HBV) reactivation in HBsAg negative/HBcAb positive lymphoma patients treated with R-CHOP-like regimen: A prospective study.
Authors: Dongmei Ji, Junning Cao, Xiaonan Hong, Ye Guo
Journal: Journal of Clinical Oncology (2015)

e19503 Background: The incidence of hepatitis B virus (HBV) reactivation in lymphoma patients with prior resolved hepatitis B who receive immunochemotherapy varies in different reports, thus leads to the controversy of antiviral prophylaxis in this patient population. The aim of this study was to identify the incidence of HBV reactivation in Diffuse Large B Cell lymphoma (DLBCL) or high grade Follicular lymphoma (FL) patients with prior resolved hepatitis B undergoing RCHOP-like therapy without prophylactic anti-HBV treatment. Methods: Chemo-naïve DLBCL or high-grade FL patients with resolved hepatitis B were treated with RCHOP-like regimen. Serum alanine transaminase (ALT), HBsAg, HBsAb, HBeAg, HBeAb and HBcAb status, HBV-DNA titer and hepatitis C virus antibody were detected before, during and after the immunochemotherapy regularly. HBV reactivation was defined as HBV-DNA level exceeded the minimum quantifiable value (500 IU/mL) or HBsAg seroconversion. Once the reactivation occurred, Anti-viral medication was given immediately. Results: Between Oct, 2010 and Oct, 2013, a total of 116 patients were included in this study. 96 patients were analyzed as the per protocol set. During a median follow up time of 28 months, 3 (3.125%) patients had HBV reactivation, 2 of them recovered after receiving the nucleotide analogues (NA). The third patient had HBsAg seroconversion after two cycles of therapy with undetectable HBV-DNA and normal ALT level and Entecavir was prescribed to him. His serum was still HBsAg positive, HBV-DNA undetectable with normal ALT level when detection repeated after the 4th cycle. This patient died of pneumonia after the 5th cycle of immunochemotherapy. Hepatitis occurred in 22 patients (22.9%), one was attributable to HBV reactivation. Conclusions: In our study, the HBV reactivation rate was relatively low in HBsAg positive/HBcAb negative patients treated with RCHOP-like regimen. Serum HBV-DNA levels should be monitored before, during and after immunochemotherapy closely. The clinical outcome of HBV-reactivation in this patient population is good when NA administered immediately after the reactivation. Clinical trial information: NCT01210287.
Evaluation for Fibrosis After Cure of Hepatitis C
Authors: Brett G. Fischer, Amiran Baduashvili, Arthur T. Evans
Journal: JAMA (2019)

To the Editor We are concerned about 2 comments that Dr Wilder and colleagues1 made in their discussion of a patient with cured chronic hepatitis C virus (HCV) infection who underwent vibration-controlled transient elastography (VCTE) testing.
Association of the Infant Gut Microbiome With Early Childhood Neurodevelopmental Outcomes
Authors: Joanne E. Sordillo, Susan Korrick, Nancy Laranjo, Vincent Carey, George M. Weinstock, Diane R. Gold, George O’Connor, Megan Sandel, Leonard B. Bacharier, Avraham Beigelman, Robert Zeiger, Augusto A. Litonjua, Scott T. Weiss
Journal: JAMA Network Open (2019)

<h3>Importance</h3> In animal models, the early life gut microbiome influences later neurodevelopment. Corresponding data in human populations are lacking. <h3>Objective</h3> To study associations between the gut microbiome in infants and development at preschool age measured by the Ages and Stages Questionnaire, third edition (ASQ-3). <h3>Design, Setting, and Participants</h3> This ancillary cohort study of the Vitamin D Antenatal Asthma Reduction Trial (VDAART) used data from 715 participants who had development assessed at 3 years of age by the ASQ-3, which included scores in 5 domains (gross motor skills, fine motor skills, problem solving, communication, and personal and social skills). A total of 309 stool samples were collected from infants aged 3 to 6 months for microbiome analysis using<i>16S rRNA</i>gene sequencing. <h3>Exposures</h3> Infant gut microbiome. <h3>Main Outcomes and Measures</h3> Continuous ASQ-3 scores and typical vs potential delay in the 5 developmental domains. Factor scores for bacterial coabundance groups were used as predictors in regression models of continuous ASQ-3 scores. Logistic regression was used to examine bacterial coabundance scores and odds of scoring below the threshold for typical development. Multivariate analysis examined the abundance of individual taxa and ASQ-3 scores. <h3>Results</h3> The 309 participants (170 [55.0%] male) with ASQ-3 scores and stool samples were ethnically diverse (136 [44.0%] black, 41 [13.3%] Hispanic, 86 [27.8%] white, and 46 [14.9%] other race/ethnicity); the mean (SD) age at ASQ-3 assessment was 3.0 (0.07) years. Coabundance scores dominated by Clostridiales (Lachnospiraceae genera and other, unclassified Clostridiales taxa) were associated with poorer ASQ-3 communication (β, –1.12; 95% CI, −2.23 to −0.01;<i>P</i> = .05) and personal and social (β, –1.44; 95% CI, −2.47 to −0.40;<i>P</i> = .01) scores and with increased odds of potential delay for communication (odds ratio [OR], 1.69; 95% CI, 1.06 to 2.68) and personal and social skills (OR, 1.96; 95% CI, 1.22 to 3.15) per unit increase in coabundance score. The<i>Bacteroides</i>-dominated coabundance grouping was associated with poorer fine motor scores (β, –2.42; 95% CI, −4.29 to −0.55;<i>P</i> = .01) and with increased odds of potential delay for fine motor skills (OR, 1.52; 95% CI, 1.07 to 2.16) per unit increase in coabundance score. Multivariate analysis detected similar family-level and order-level associations. <h3>Conclusions and Relevance</h3> These findings suggest an association between infant gut microbiome composition and communication, personal and social, and fine motor skills at age 3 years. The majority of associations were driven by taxa within the order Clostridiales.
FRI-009-Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements
Authors: Christophe Corpechot, Alexandra Rousseau, Sara Lemoinne, Gaouar Farid, Karima Ben Belkacem, Raoul Poupon, Olivier Chazouillères
Journal: Journal of Hepatology (2019)